SCHEMBL797411

SCHEMBL797411

C1CC(OCC2CCNCC2)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.38
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
CTSK P43235 1/20 0.37
CYP2D6 P10635 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
SLC6A4 P31645 7/20 0.36
SLC6A2 P23975 6/20 0.36
HTR3A P46098 3/20 0.36
KCNH2 Q12809 2/20 0.36
TPSAB1 Q15661 2/20 0.36
TPSD1 Q9BZJ3 2/20 0.36
TPSG1 Q9NRR2 2/20 0.36
SLC6A3 Q01959 5/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
GBA1 P04062 2/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
HTR7 P34969 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17220300 0.98 TDP1 (0.41) TDP1CTSLCTSBCTSKCYP2D6
Hydrochloric Acid SCHEMBL7491956 0.91 CTSL (0.43) TDP1CTSLCTSBCTSKCYP2D6
SCHEMBL4104818 0.91 CTSL (0.41) TDP1CTSLCTSBCTSKCYP2D6
SCHEMBL470809 0.91 TDP1 (0.40) TDP1CTSLCTSBCTSKCYP2D6
SCHEMBL19025161 0.86 CTSL (0.46) TDP1CTSLCTSBCTSKCYP2D6
SCHEMBL796522 0.86 SLC6A2 (0.37) TDP1CTSLCTSBCTSKSLC6A4
SCHEMBL18509263 0.84 CTSL (0.48) TDP1CTSLCTSBCTSKSLC6A4
Hydrochloric Acid SCHEMBL17220374 0.84 TDP1 (0.39) TDP1CTSLCTSBCTSKSLC6A4
SCHEMBL25689668 0.83
SCHEMBL13747906 0.82 TDP1 (0.38) TDP1CTSLCTSBCTSKCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150025057-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2015-01-22 US disclosed
US-8895733-B2 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-11-25 US disclosed
US-20140051676-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-02-20 US disclosed
EP-2616465-A1 TRIAZINE-OXADIAZOLES Novartis AG (CH) 2013-07-24 EP disclosed
WO-2012035023-A1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025057-A1 Triazine-oxadiazoles OPRK1, OPRD1, OPRL1 TDP1 4176/4885CTSL 4722/4885CTSB 4006/4885
US-20140051676-A1 Triazine-oxadiazoles OPRK1, OPRD1, OPRL1 TDP1 4176/4885CTSL 4722/4885CTSB 4006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.